Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis

BACKGROUND: Immunoglobulin light-chain amyloidosis (AL amyloidosis) is a rare and often fatal disease for which there is currently no treatment approved by the US Food and Drug Administration or the European Medicines Agency. Treatment options, which are typically based on therapies for multiple mye...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am Health Drug Benefits
Hlavní autoři: Rizio, Avery A., White, Michelle K., McCausland, Kristen L., Quock, Tiffany P., Guthrie, Spencer D., Yokota, Miyo, Bayliss, Martha S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Engage Healthcare Communications, LLC 2018
Témata:
Clinical
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6306096/
https://ncbi.nlm.nih.gov/pubmed/30647830
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky